<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01362114</url>
  </required_header>
  <id_info>
    <org_study_id>B080009</org_study_id>
    <nct_id>NCT01362114</nct_id>
  </id_info>
  <brief_title>The Effect of Sihogayonggolmoryeo-tang on the Anxiety of Hwa-byung</brief_title>
  <official_title>Phase 4 Study of The Effect of Sihogayonggolmoryeo-tang on the Anxiety of Hwa-byung : A Randomized, Double Blind, Placebo-control Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korea Health Industry Development Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Korea Health Industry Development Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this randomized, double blinded, Placebo-control Trial, the investigators planned to give
      Sihogayonggolmoryeo-tang extract or controlled medication on the Anxiety of Hwa-byung.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2010</start_date>
  <completion_date type="Anticipated">June 2012</completion_date>
  <primary_completion_date type="Anticipated">May 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hamilton Anxiety Scale(HAM-A)</measure>
    <time_frame>8 weeks</time_frame>
    <description>The HAM-A (Hamilton Anxiety Scale) is a widely used interview scale that measures the severity of a patient's anxiety, based on 14 parameters, including anxious mood, tension, fears, insomnia, somatic complaints and behavior at the interview.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>State-Trait Anxiety Inventory(STAI)</measure>
    <time_frame>8 weeks</time_frame>
    <description>The State-Trait Anxiety Inventory (STAI) was initially conceptualized as a research instrument for the study of anxiety in adults. It is a self-report assessment device which includes separate measures of state and trait anxiety.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beck Depression Inventory(BDI)</measure>
    <time_frame>8 weeks</time_frame>
    <description>BDI is a 21-question multiple-choice self-report inventory, one of the most widely used instruments for measuring the severity of depression. Each question has a set of at least four possible answer choices, ranging in intensity. When the test is scored, a value of 0 to 3 is assigned for each answer and then the total score is compared to a key to determine the depression's severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WHO Quality of Life Abbreviated(WHOQOL-BREF)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Quality of life is used to evaluate the general well-being of individuals and societies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Rate Variability(HRV)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Heart rate variability (HRV) is a physiological phenomenon where the time interval between heart beats varies. It is measured by the variation in the beat-to-beat interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>likert scale</measure>
    <time_frame>8 weeks</time_frame>
    <description>This scale is used to evaluate the degree of Hwa-byung's major symptom by 5 point measure. (0,1,2,3,4)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hwa-byung scale</measure>
    <time_frame>8 weeks</time_frame>
    <description>This scale is used for self report to evaluate the Hwa-byung's emotional symptoms, physical symptoms and personality traits by 5 point.(0,1,2,3,4).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>State-Trait Anger Expression Inventory (STAXI)</measure>
    <time_frame>8 weeks</time_frame>
    <description>The State-Trait Anger Expression Inventory is a inventory which measures the intensity of anger as an emotional state (State Anger) and the disposition to experience angry feelings as a personality trait (Trait Anger). Items consist of 4-point scales that assess intensity of anger at a particular moment and the frequency of anger experience, expression, and control.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insomnia Severity Index (ISI)</measure>
    <time_frame>8 weeks</time_frame>
    <description>The Insomnia Severity Index is a series of questions, seven in total, designed by medical professionals to help gauge the seriousness of a person's insomnia. The seven questions have numerical value, and the total is added up at the end of the process to give a total that symbolizes the seriousness of the problem</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Instrument of Oriental Medical Evaluation for Hwa-Byung</measure>
    <time_frame>8 weeks</time_frame>
    <description>Instrument of Oriental Medical Evaluation for Hwa-Byung is a standard scale to evaluate for Oriental Medical cure in Hwa-Byung</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Hwa-byung</condition>
  <arm_group>
    <arm_group_label>Sihogayonggolmoryeo-tang extract</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>name of product: 'SIHOGAYONGGOLMORYU TANG EXTRACT GRAN'
standard code for item: 200005676
shape, type: extract(brown)
usage, content: adults;three times a day, each taken before or between meals
dose, standard: 2.5g for each sack, capsulated
storage : airtight container, stored in room temperature
expiration date : 36months after manufacture
macufacturing company: KyungBangnShinYak inc.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo; corn flour,</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>raw material: total contents(500㎎); cornstarch 50.0%(250.0㎎), 당수화물 49.45%(247.25㎎), caramel pigment 0.5%(2.5㎎), SsangHwa fragrance 0.05%(0.25㎎)
shape, type: extract(brown)
usage, dose: adults: three times a day, 1 sack before or between meals
dose, standard: 2.5g for each sack, capsulated
storage : airtight container, stored in room temperature
expiration date : 36 months after manufacture
manufacturing company: KyungBangnShinYak inc.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SIHOGAYONGGOLMORYU TANG EXTRACT GRAN</intervention_name>
    <description>three times a day, AC 30 min., 4 capsules taken each time (4capsules=2.5g), 8 weeks</description>
    <arm_group_label>Sihogayonggolmoryeo-tang extract</arm_group_label>
    <other_name>standard code for item: 200005676</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>three times a day, AC 30 min., 4 capsules taken each time (4capsules=2.5g), 8 weeks.</description>
    <arm_group_label>Placebo; corn flour,</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male or female aged 20-65

          -  subjects who meet structured interview criteria for Hwa-Byung Diagnosis

          -  subjects who have axiety (more than 17 score in HAMA)

        Exclusion Criteria:

          -  duration of illness less than 6 months

          -  current or past history of delusions, hallucination

          -  past history of at least one manic episode, hypomanic episode, or mixed episode

          -  current or past history of alcohol abuse or alcohol dependence history

          -  taking substances(e.g. steroids) which might affect symptoms

          -  medical conditions(e.g. hyperthyroidism, hypothyroidism, heart disease) that might
             affect symptoms

          -  current with hepatoma, hepatic cirrhosis, chronic renal failure, congestive heart
             failure

          -  pregnancy, lactation, women not using medically accepted means of birth control

          -  considered not apt to carry out clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>In-Chul Jung, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oriental Hospital of Daejon University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>BOK NAM SEO</last_name>
    <email>florence73@hanmail.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>Oriental Hospital of Daejon University</name>
      <address>
        <city>Daejon</city>
        <state>Choong-Chung-Do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dae-Myung Park</last_name>
      <phone>82-42-470-9562</phone>
      <email>pdm8210@hanmail.net</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 25, 2011</study_first_submitted>
  <study_first_submitted_qc>May 26, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2011</study_first_posted>
  <last_update_submitted>April 16, 2012</last_update_submitted>
  <last_update_submitted_qc>April 16, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 18, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Korea Health Industry Development Institute</investigator_affiliation>
    <investigator_full_name>In-Chul Jung</investigator_full_name>
    <investigator_title>Professor of Oriental Hospital of Daejon University</investigator_title>
  </responsible_party>
  <keyword>Hwa-byung</keyword>
  <keyword>Sihogayonggolmoryeo-tang</keyword>
  <keyword>Anxiety</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

